Search
ravulizumab (Ultomiris)
Indications:
- paroxysmal nocturnal hemoglobinuria
Dosage:
- every 8 weeks
* immunization with meningococcal vaccines >= 2 weeks prior to 1st dose of ravulizumab
Adverse effects:
- headache
- upper respiratory infection
Boxed Warning
- risk of life-threatening meningococcal infections & sepsis
- vaccination reduces, but does not eliminate, risk of meningococcal infection
Mechanism of action:
- long-acting complement inhibitor that prevents hemolysis
- binds complement C5 & inhibits terminal complement cascade
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
hematologic agent
pharmaceutical monoclonal antibody
References
- FDA News Release. Dec 21, 2018
FDA approves new treatment for adult patients with rare, life-
threatening blood disease.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629022.htm